Harnessing the immune system for the treatment of non-small-cell lung cancer

Research output: Contribution to journalArticle

Abstract

Over the last several years, new therapeutic targets have emerged in immunotherapy, particularly the immune checkpoint pathways. Blocking inhibitory pathways via monoclonal antibodies, such as the anti- cytotoxic T-lymphocyte antigen-4 antibody (ipilimumab), anti-programmed cell death-1 antibody (BMS-936558), and anti-programmed cell death-1 ligand antibody (BMS-936559), has the ability to break down the shield that tumors co-opt for their defense. Vaccines are able to help the immune system develop immune memory that can have long-lasting, tumor-specific effects. Newer vaccines, particularly the tumor cell vaccine, belagenpumatucel-L, and the antigen-specific vaccines, melanoma-associated antigen-A3, liposomal BLP-25, TG4010, and recombinant human epidermal growth factor, are being evaluated in some of the largest trials ever attempted in lung cancer therapy. These therapies alone or in combination may hold the key to making immunotherapy a reality in the treatment of lung cancer.

Original languageEnglish (US)
Pages (from-to)1021-1028
Number of pages8
JournalJournal of Clinical Oncology
Volume31
Issue number8
DOIs
StatePublished - Mar 10 2013

Fingerprint

Non-Small Cell Lung Carcinoma
Immune System
Vaccines
Immunotherapy
Lung Neoplasms
Cell Death
CTLA-4 Antigen
Melanoma-Specific Antigens
Cancer Vaccines
Antibodies
Therapeutics
Epidermal Growth Factor
Anti-Idiotypic Antibodies
Neoplasms
Monoclonal Antibodies
Ligands
Antigens

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Harnessing the immune system for the treatment of non-small-cell lung cancer. / Brahmer, Julie.

In: Journal of Clinical Oncology, Vol. 31, No. 8, 10.03.2013, p. 1021-1028.

Research output: Contribution to journalArticle

@article{57ca428dfeb2494eb6d9c7538e2a75d7,
title = "Harnessing the immune system for the treatment of non-small-cell lung cancer",
abstract = "Over the last several years, new therapeutic targets have emerged in immunotherapy, particularly the immune checkpoint pathways. Blocking inhibitory pathways via monoclonal antibodies, such as the anti- cytotoxic T-lymphocyte antigen-4 antibody (ipilimumab), anti-programmed cell death-1 antibody (BMS-936558), and anti-programmed cell death-1 ligand antibody (BMS-936559), has the ability to break down the shield that tumors co-opt for their defense. Vaccines are able to help the immune system develop immune memory that can have long-lasting, tumor-specific effects. Newer vaccines, particularly the tumor cell vaccine, belagenpumatucel-L, and the antigen-specific vaccines, melanoma-associated antigen-A3, liposomal BLP-25, TG4010, and recombinant human epidermal growth factor, are being evaluated in some of the largest trials ever attempted in lung cancer therapy. These therapies alone or in combination may hold the key to making immunotherapy a reality in the treatment of lung cancer.",
author = "Julie Brahmer",
year = "2013",
month = "3",
day = "10",
doi = "10.1200/JCO.2012.45.8703",
language = "English (US)",
volume = "31",
pages = "1021--1028",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

TY - JOUR

T1 - Harnessing the immune system for the treatment of non-small-cell lung cancer

AU - Brahmer, Julie

PY - 2013/3/10

Y1 - 2013/3/10

N2 - Over the last several years, new therapeutic targets have emerged in immunotherapy, particularly the immune checkpoint pathways. Blocking inhibitory pathways via monoclonal antibodies, such as the anti- cytotoxic T-lymphocyte antigen-4 antibody (ipilimumab), anti-programmed cell death-1 antibody (BMS-936558), and anti-programmed cell death-1 ligand antibody (BMS-936559), has the ability to break down the shield that tumors co-opt for their defense. Vaccines are able to help the immune system develop immune memory that can have long-lasting, tumor-specific effects. Newer vaccines, particularly the tumor cell vaccine, belagenpumatucel-L, and the antigen-specific vaccines, melanoma-associated antigen-A3, liposomal BLP-25, TG4010, and recombinant human epidermal growth factor, are being evaluated in some of the largest trials ever attempted in lung cancer therapy. These therapies alone or in combination may hold the key to making immunotherapy a reality in the treatment of lung cancer.

AB - Over the last several years, new therapeutic targets have emerged in immunotherapy, particularly the immune checkpoint pathways. Blocking inhibitory pathways via monoclonal antibodies, such as the anti- cytotoxic T-lymphocyte antigen-4 antibody (ipilimumab), anti-programmed cell death-1 antibody (BMS-936558), and anti-programmed cell death-1 ligand antibody (BMS-936559), has the ability to break down the shield that tumors co-opt for their defense. Vaccines are able to help the immune system develop immune memory that can have long-lasting, tumor-specific effects. Newer vaccines, particularly the tumor cell vaccine, belagenpumatucel-L, and the antigen-specific vaccines, melanoma-associated antigen-A3, liposomal BLP-25, TG4010, and recombinant human epidermal growth factor, are being evaluated in some of the largest trials ever attempted in lung cancer therapy. These therapies alone or in combination may hold the key to making immunotherapy a reality in the treatment of lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=84875936184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875936184&partnerID=8YFLogxK

U2 - 10.1200/JCO.2012.45.8703

DO - 10.1200/JCO.2012.45.8703

M3 - Article

VL - 31

SP - 1021

EP - 1028

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -